Rating scales for cognition in Huntington's disease: Critique and recommendations

Tiago A. Mestre, Anne Catherine Bachoud-Lévi, Johan Marinus, Julie C. Stout, Jane S. Paulsen, Peter Como, Kevin Duff, Cristina Sampaio, Christopher G. Goetz, Esther Cubo, Glenn T. Stebbins, Pablo Martinez-Martin, the Members of the MDS Committee on Rating Scales Development

Research output: Contribution to journalReview ArticleResearchpeer-review

Abstract

Cognitive impairment is one of the main features of Huntington's disease and is present across the disease spectrum. As part of the International Parkinson's Disease and Movement Disorder Society-sponsored project to review all clinical rating scales used in Huntington's disease, a systematic review of the literature was performed to identify cognitive scales used in Huntington's disease and make recommendations for their use. A total of 17 cognitive scales were identified and evaluated. None of the scales met criteria for a “recommended” status. For assessing severity of cognitive dysfunction, the Montreal Cognitive Assessment was “recommended with caveats.” The UHDRS Cognitive Assessment, the UHDRS-For Advanced Patients cognitive section, the Alzheimer's Disease Assessment Scale-Cognitive Subscale, the Frontal Assessment Battery, the Mattis Dementia Rating Scale, the Mini-Mental State Examination, and the Repeatable Battery for the Assessment of Neuropsychological Status were “suggested” for evaluating severity of cognitive impairment. The MoCA was “suggested” as a screening tool for cognitive impairment. The major challenge in the assessment of cognition in Huntington's disease is the lack of a formal definition of dementia and/or mild cognitive impairment in this disease. The committee concluded that there is a need to further validate currently available cognitive scales in Huntington's disease, but that it is premature to recommend the development of new scales. Recently developed Huntington's disease-specific scales, such as the Huntington's Disease-Cognitive Assessment Battery, hold promise but require the completion of more comprehensive clinimetric development.

Original languageEnglish
Pages (from-to)187-195
Number of pages9
JournalMovement Disorders
Volume33
Issue number2
DOIs
Publication statusPublished - 1 Feb 2018

Keywords

  • clinimetrics
  • cognition
  • Huntington's disease
  • rating scales
  • validation

Cite this

Mestre, T. A., Bachoud-Lévi, A. C., Marinus, J., Stout, J. C., Paulsen, J. S., Como, P., ... the Members of the MDS Committee on Rating Scales Development (2018). Rating scales for cognition in Huntington's disease: Critique and recommendations. Movement Disorders, 33(2), 187-195. https://doi.org/10.1002/mds.27227
Mestre, Tiago A. ; Bachoud-Lévi, Anne Catherine ; Marinus, Johan ; Stout, Julie C. ; Paulsen, Jane S. ; Como, Peter ; Duff, Kevin ; Sampaio, Cristina ; Goetz, Christopher G. ; Cubo, Esther ; Stebbins, Glenn T. ; Martinez-Martin, Pablo ; the Members of the MDS Committee on Rating Scales Development. / Rating scales for cognition in Huntington's disease : Critique and recommendations. In: Movement Disorders. 2018 ; Vol. 33, No. 2. pp. 187-195.
@article{01b63d11c693446fa78ff8121863c603,
title = "Rating scales for cognition in Huntington's disease: Critique and recommendations",
abstract = "Cognitive impairment is one of the main features of Huntington's disease and is present across the disease spectrum. As part of the International Parkinson's Disease and Movement Disorder Society-sponsored project to review all clinical rating scales used in Huntington's disease, a systematic review of the literature was performed to identify cognitive scales used in Huntington's disease and make recommendations for their use. A total of 17 cognitive scales were identified and evaluated. None of the scales met criteria for a “recommended” status. For assessing severity of cognitive dysfunction, the Montreal Cognitive Assessment was “recommended with caveats.” The UHDRS Cognitive Assessment, the UHDRS-For Advanced Patients cognitive section, the Alzheimer's Disease Assessment Scale-Cognitive Subscale, the Frontal Assessment Battery, the Mattis Dementia Rating Scale, the Mini-Mental State Examination, and the Repeatable Battery for the Assessment of Neuropsychological Status were “suggested” for evaluating severity of cognitive impairment. The MoCA was “suggested” as a screening tool for cognitive impairment. The major challenge in the assessment of cognition in Huntington's disease is the lack of a formal definition of dementia and/or mild cognitive impairment in this disease. The committee concluded that there is a need to further validate currently available cognitive scales in Huntington's disease, but that it is premature to recommend the development of new scales. Recently developed Huntington's disease-specific scales, such as the Huntington's Disease-Cognitive Assessment Battery, hold promise but require the completion of more comprehensive clinimetric development.",
keywords = "clinimetrics, cognition, Huntington's disease, rating scales, validation",
author = "Mestre, {Tiago A.} and Bachoud-L{\'e}vi, {Anne Catherine} and Johan Marinus and Stout, {Julie C.} and Paulsen, {Jane S.} and Peter Como and Kevin Duff and Cristina Sampaio and Goetz, {Christopher G.} and Esther Cubo and Stebbins, {Glenn T.} and Pablo Martinez-Martin and {the Members of the MDS Committee on Rating Scales Development}",
year = "2018",
month = "2",
day = "1",
doi = "10.1002/mds.27227",
language = "English",
volume = "33",
pages = "187--195",
journal = "Movement Disorders",
issn = "0885-3185",
publisher = "Wiley-Blackwell",
number = "2",

}

Mestre, TA, Bachoud-Lévi, AC, Marinus, J, Stout, JC, Paulsen, JS, Como, P, Duff, K, Sampaio, C, Goetz, CG, Cubo, E, Stebbins, GT, Martinez-Martin, P & the Members of the MDS Committee on Rating Scales Development 2018, 'Rating scales for cognition in Huntington's disease: Critique and recommendations' Movement Disorders, vol. 33, no. 2, pp. 187-195. https://doi.org/10.1002/mds.27227

Rating scales for cognition in Huntington's disease : Critique and recommendations. / Mestre, Tiago A.; Bachoud-Lévi, Anne Catherine; Marinus, Johan; Stout, Julie C.; Paulsen, Jane S.; Como, Peter; Duff, Kevin; Sampaio, Cristina; Goetz, Christopher G.; Cubo, Esther; Stebbins, Glenn T.; Martinez-Martin, Pablo; the Members of the MDS Committee on Rating Scales Development.

In: Movement Disorders, Vol. 33, No. 2, 01.02.2018, p. 187-195.

Research output: Contribution to journalReview ArticleResearchpeer-review

TY - JOUR

T1 - Rating scales for cognition in Huntington's disease

T2 - Critique and recommendations

AU - Mestre, Tiago A.

AU - Bachoud-Lévi, Anne Catherine

AU - Marinus, Johan

AU - Stout, Julie C.

AU - Paulsen, Jane S.

AU - Como, Peter

AU - Duff, Kevin

AU - Sampaio, Cristina

AU - Goetz, Christopher G.

AU - Cubo, Esther

AU - Stebbins, Glenn T.

AU - Martinez-Martin, Pablo

AU - the Members of the MDS Committee on Rating Scales Development

PY - 2018/2/1

Y1 - 2018/2/1

N2 - Cognitive impairment is one of the main features of Huntington's disease and is present across the disease spectrum. As part of the International Parkinson's Disease and Movement Disorder Society-sponsored project to review all clinical rating scales used in Huntington's disease, a systematic review of the literature was performed to identify cognitive scales used in Huntington's disease and make recommendations for their use. A total of 17 cognitive scales were identified and evaluated. None of the scales met criteria for a “recommended” status. For assessing severity of cognitive dysfunction, the Montreal Cognitive Assessment was “recommended with caveats.” The UHDRS Cognitive Assessment, the UHDRS-For Advanced Patients cognitive section, the Alzheimer's Disease Assessment Scale-Cognitive Subscale, the Frontal Assessment Battery, the Mattis Dementia Rating Scale, the Mini-Mental State Examination, and the Repeatable Battery for the Assessment of Neuropsychological Status were “suggested” for evaluating severity of cognitive impairment. The MoCA was “suggested” as a screening tool for cognitive impairment. The major challenge in the assessment of cognition in Huntington's disease is the lack of a formal definition of dementia and/or mild cognitive impairment in this disease. The committee concluded that there is a need to further validate currently available cognitive scales in Huntington's disease, but that it is premature to recommend the development of new scales. Recently developed Huntington's disease-specific scales, such as the Huntington's Disease-Cognitive Assessment Battery, hold promise but require the completion of more comprehensive clinimetric development.

AB - Cognitive impairment is one of the main features of Huntington's disease and is present across the disease spectrum. As part of the International Parkinson's Disease and Movement Disorder Society-sponsored project to review all clinical rating scales used in Huntington's disease, a systematic review of the literature was performed to identify cognitive scales used in Huntington's disease and make recommendations for their use. A total of 17 cognitive scales were identified and evaluated. None of the scales met criteria for a “recommended” status. For assessing severity of cognitive dysfunction, the Montreal Cognitive Assessment was “recommended with caveats.” The UHDRS Cognitive Assessment, the UHDRS-For Advanced Patients cognitive section, the Alzheimer's Disease Assessment Scale-Cognitive Subscale, the Frontal Assessment Battery, the Mattis Dementia Rating Scale, the Mini-Mental State Examination, and the Repeatable Battery for the Assessment of Neuropsychological Status were “suggested” for evaluating severity of cognitive impairment. The MoCA was “suggested” as a screening tool for cognitive impairment. The major challenge in the assessment of cognition in Huntington's disease is the lack of a formal definition of dementia and/or mild cognitive impairment in this disease. The committee concluded that there is a need to further validate currently available cognitive scales in Huntington's disease, but that it is premature to recommend the development of new scales. Recently developed Huntington's disease-specific scales, such as the Huntington's Disease-Cognitive Assessment Battery, hold promise but require the completion of more comprehensive clinimetric development.

KW - clinimetrics

KW - cognition

KW - Huntington's disease

KW - rating scales

KW - validation

UR - http://www.scopus.com/inward/record.url?scp=85039156724&partnerID=8YFLogxK

U2 - 10.1002/mds.27227

DO - 10.1002/mds.27227

M3 - Review Article

VL - 33

SP - 187

EP - 195

JO - Movement Disorders

JF - Movement Disorders

SN - 0885-3185

IS - 2

ER -

Mestre TA, Bachoud-Lévi AC, Marinus J, Stout JC, Paulsen JS, Como P et al. Rating scales for cognition in Huntington's disease: Critique and recommendations. Movement Disorders. 2018 Feb 1;33(2):187-195. https://doi.org/10.1002/mds.27227